相关实验视频

Updated: Jul 24, 2025

Novel and Innovative Hybrid Technique for Type A Aortic Dissection

Novel and Innovative Hybrid Technique for Type A Aortic Dissection

Published on: March 28, 2025

由血管内皮生长因子抑制剂诱导的大动脉剖析

Shuqi Dai¹, Yu Zhong¹, Hongxia Cui¹

¹Department of Pharmacy, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China.

Frontiers in pharmacology

|July 10, 2023

概括

在癌症治疗中使用的血管内皮生长因子抑制剂 (VEGFI) 与大动脉剖析有关,这是一个严重的不良反应. 需要进一步的研究来证实这种关联,并指导患者的护理.

科学领域:

在瘤学瘤学.
心血管医学心血管医学
药理学药理学是指药理学的学科.

背景情况:

血管内皮生长因子 (VEGF) 驱动血管新生,对瘤生长至关重要.
血管内皮生长因子抑制剂 (VEGFI) 用于抗癌治疗.
大动脉解剖 (AD) 是与VEGFI治疗相关的罕见但严重的不良反应.

研究的目的:

审查和综合现有的VEGFI相关的大动脉剖析案例报告.
讨论接受VEGFI治疗的患者的AD病理机制,风险因素,诊断方法和治疗策略.

主要方法:

在PubMed和CNKI数据库进行系统的文献搜索,截至2022年4月28日.
包括病例报告,详细说明VEGFI的使用和随后的大动脉剖析.
分析了17个选定的案例报告.

主要成果:

这项研究确定了八种与大动脉剖析相关的VEGFI药物:苏尼替尼,索拉芬尼,帕佐帕尼尼,阿克西替尼,阿帕蒂尼布,安洛提尼布,贝瓦西祖马布和拉穆西鲁马布.
病例报告表明,VEGFI与大动脉解剖发生之间存在潜在的关联.
目前缺乏关于人口水平风险的明确统计证据.

结论:

血管内皮生长因子抑制剂与大动脉剖析有关.
虽然在大量人群中没有得到统计学上的证实,但审查的病例突出了对意识的关键需求.
需要进一步研究以确定因果关系,并优化在VEGFI治疗期间患有AD的患者的管理策略.

关键词:

不良反应不良反应大动脉切割剖析.药物安全药物安全这种高血压,高血压.血管内皮生长因子抑制剂血管内皮生长因子抑制剂

更多相关视频

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases

Precision Ultrasound-guided Stem Cell Delivery for Vascular Repair in Aortic Diseases

Published on: June 20, 2025

A New Murine Model of Endovascular Aortic Aneurysm Repair

A New Murine Model of Endovascular Aortic Aneurysm Repair

Published on: July 7, 2013

相关概念视频

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Aneurysm III: Interprofessional Care

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...

Aneurysm I: Introduction

Aneurysm I: Introduction

An aortic aneurysm is a localized outpouching or dilation at a weak point in the artery wall. It may involve different parts of the aorta, such as the abdominal aorta, aortic arch, or thoracic aorta.Etiological factorsSeveral disorders are associated with aortic aneurysms.Congenital causes, such as primary connective tissue disorders like Marfan syndrome, impact the integrity and strength of connective tissues, notably affecting the aorta. Marfan syndrome is a genetic disorder that specifically...